An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data

INTRODUCTION: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). OBJECTIVE: Our objective was to compare the incidence rates (IRs) of adverse events in tofacitinib clinical trials and real-world observational data for alternative treatments. METHODS: The to...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Gerd R., Curtis, Jeffrey R., Yun, Huifeng, FitzGerald, Oliver, Winthrop, Kevin L., Azevedo, Valderilio F., Rigby, William F. C., Kanik, Keith S., Wang, Cunshan, Biswas, Pinaki, Jones, Thomas, Palmetto, Niki, Hendrikx, Thijs, Menon, Sujatha, Rojo, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105422/
https://www.ncbi.nlm.nih.gov/pubmed/32006348
http://dx.doi.org/10.1007/s40264-020-00904-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105422/
https://www.ncbi.nlm.nih.gov/pubmed/32006348
http://dx.doi.org/10.1007/s40264-020-00904-9

Ejemplares similares